Form 4: Myomo Director Buys 70,000 Shares in Open Market

Myomo, Inc. Director Heather C. Getz acquired 70,000 shares of common stock at an average price of $0.728 per share on March 12, 2026.

Summary

• Heather C. Getz, a Director of Myomo, Inc. (MYO), purchased 70,000 shares of common stock.
• The transaction occurred on March 12, 2026, through open market purchases.
• The weighted average purchase price was $0.728 per share, with individual lots ranging from $0.72 to $0.73.
• Following this acquisition, Ms. Getz beneficially owns a total of 111,754 shares of Myomo common stock.
• The purchase was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's open market purchase indicates confidence in the company's valuation and future prospects, especially when executed under a 10b5-1 plan.

Positives

• A director's open market purchase of 70,000 shares signals confidence in the company's future prospects and current valuation.
• The transaction was executed under a Rule 10b5-1 plan, suggesting a deliberate and pre-planned investment strategy by the insider.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which primarily reports an insider transaction.

Industry Context

StockSavvy.ai notes that insider buying, especially by a director, can often be interpreted by the market as a positive signal, suggesting that those closest to the company believe its stock is undervalued or has strong future potential. This is particularly relevant in the medical device or rehabilitation technology sector where Myomo operates, as it can indicate confidence in product adoption or market expansion.

Comparison to Industry Standards

• Insider buying activity is a common indicator tracked by investors across all industries. While there's no direct 'industry standard' for the *amount* of insider buying, a purchase of 70,000 shares by a director, increasing their holdings to over 111,000 shares, represents a significant personal investment relative to the company's stock price.
• For comparison, similar insider purchases in other small-cap medical technology companies, such as those seen in early-stage biotech firms like AxoGen (AXGN) or electroceutical companies, often precede periods of increased investor interest or positive news flow, though this is not a guarantee.

Corporate Governance

Related Party Transactions

• The purchase of 70,000 shares of common stock by Director Heather C. Getz is a related party transaction, routinely disclosed as an insider trading event.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive indicator of management confidence, potentially influencing investor sentiment.

Next Steps

• The reporting party agrees to provide details of the transactions to the SEC upon request.

Key Dates

Recommendation

A director's open market purchase of shares is a positive signal, indicating confidence in the company's future. However, without additional financial or strategic updates, this single transaction primarily reinforces a 'hold' position for seasoned investors, suggesting continued monitoring of the company's performance and broader market conditions. It's a good sign, but not a definitive catalyst for a 'buy' recommendation on its own.

Keywords

Myomo, MYO, Insider Buying, Director Purchase, Stock Acquisition, Form 4, Heather C. Getz, 10b5-1 Plan, Common Stock